Ricco Gabriele, Bonino Ferruccio, Lanza Maria, Scatena Fabrizio, Alfieri Carlo M, Messa Piergiorgio, Marchisio Edoardo, Mascolo Giovanni, Romanò Luisa, Galli Cristina, Li Tian-Cheng, Wakita Takaji, Miyamura Tatsuo, Brunetto Maurizia R
Hepatology Unit, University Hospital of Pisa, Pisa, Italy.
General Medicine 2 Unit and Gastroenterology Chair, University Hospital of Pisa, Italy.
Dig Liver Dis. 2016 May;48(5):536-541. doi: 10.1016/j.dld.2016.01.007. Epub 2016 Feb 10.
Hepatitis E virus (HEV) is a zoonotic agent that causes acute hepatitis in humans with sporadic infections and outbreaks in developing countries worldwide. The global spread of HEV remains underestimated because of subclinical infections and lack of sensitive diagnostic assays.
To study the prevalence of HEV antibodies (anti-HEV) in sera of blood-donors and patients with chronic-liver-disease and chronic-renal-disease, using newly developed anti-HEV assays.
396 sera from 199 blood-donors, 109 chronic-liver-disease patients and 88 chronic-renal-disease patients and three standard reference serum panels were tested in parallel with a sensitive reference anti-HEV assay and newly developed assays for IgA, IgM and total anti-HEV based on HEV-like-particles produced by recombinant baculo-viruses.
Overall, total anti-HEV was detected in 12.9% (7.0% blood-donors, 9.2% and 30.7% chronic-liver-disease patients and chronic-renal-disease patients, respectively). We observed a higher anti-HEV prevalence in older subjects and in chronic-renal-disease patients in relation with degree on immune-depression (p<0.001). Results from reference serum panels showed an optimal and slightly better performance of the new assay over the commercially available assay.
Newly developed anti-HEV assays using recombinant HEV-like-particles showed optimal diagnostic performances assessing that HEV-infection is endemic in Italy with seroprevalence ranging from 7% to 30% in blood donors and immune-compromised hosts, respectively.
戊型肝炎病毒（HEV）是一种人畜共患病原体，在全球发展中国家可导致人类散发性感染和暴发急性肝炎。由于存在亚临床感染以及缺乏敏感的诊断检测方法，HEV在全球的传播情况仍被低估。
使用新开发的抗HEV检测方法，研究献血者、慢性肝病患者和慢性肾病患者血清中抗HEV抗体（抗-HEV）的流行情况。
将来自199名献血者、109名慢性肝病患者和88名慢性肾病患者的396份血清以及三个标准参考血清组，与一种敏感的参考抗HEV检测方法以及基于重组杆状病毒产生的HEV样颗粒新开发的IgA、IgM和总抗HEV检测方法进行平行检测。
总体而言，检测到总抗HEV的比例为12.9%（献血者为7.0%，慢性肝病患者和慢性肾病患者分别为9.2%和30.7%）。我们观察到老年受试者和慢性肾病患者中抗HEV流行率较高，且与免疫抑制程度相关（p<0.001）。参考血清组的结果显示，新检测方法的性能优于市售检测方法，表现最佳且略胜一筹。
使用重组HEV样颗粒新开发的抗HEV检测方法显示出最佳诊断性能，评估出HEV感染在意大利呈地方性流行，在献血者和免疫功能低下宿主中的血清流行率分别为7%至30%。
